We are live on ! Find out more
BNTCW

Benitec Biopharma Limited
BNTCW

Delisted

BNTCW was delisted on the 14th of April, 2020.

Back to rankings

3 hedge funds and large institutions have $50K invested in Benitec Biopharma Limited in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 2 → 3 (+1)

4% less capital invested

Capital invested by funds: $52K → $50K (-$2K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$134

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$12.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$32K -$12.2K -34,970 -28%
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$18K – – –
UBS Group
3
UBS Group
Switzerland
– +$134 +385 New

BNTCW Hedge Fund Activity: Q2 2017 in Review

3 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma Limited (BNTCW) for Q2 2017, worth a combined $50K — down 3.8% from $52K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new BNTCW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $134. The largest seller was Sabby Management, cutting an estimated $12.2K.

  • 3 institutional investors held Benitec Biopharma Limited (BNTCW) as of Q2 2017, up from 2 in Q1 2017.
  • Funds reported $50K of Benitec Biopharma Limited stock for Q2 2017, down 3.8% quarter-over-quarter.
  • 1 fund opened new Benitec Biopharma Limited positions in Q2 2017 and 0 closed out, a net change of +1 holder.
  • The largest Benitec Biopharma Limited buyer in Q2 2017 was UBS Group, an estimated $134 added.
  • The largest Benitec Biopharma Limited seller in Q2 2017 was Sabby Management, an estimated $12.2K sold.

Based on aggregated 13F filings for Q2 2017.